Seven drug regulators, including the EU, UK, and Canada, have warned since 2019 that antidepressant-linked sexual side effects can persist for years after the drug is stopped. The US hasn't.
ScienceBlog (Lab Report column)
scienceblog.com2026-08
Summary (paraphrased)
A 2026 news-analysis piece mapping how seven regulators addressed persistent post-antidepressant sexual dysfunction between 2019 and 2025: the EMA's 2019 PRAC conclusion and label changes, the UK's 2019 label-level implementation, Health Canada's 2021 safety review, the TGA's 2024 product-information update, Malaysia's 2025 alert, and reported but poorly documented actions in Ireland and Hong Kong. It then documents the US gap: the FDA has no equivalent antidepressant label language, a 2018 citizen petition remains undecided, and a 2024 Public Citizen lawsuit over the delay was dismissed in 2025 on standing grounds. The piece also explains why incidence remains unknown and notes that patient leaflets in the UK were still under expert-group review as recently as 2025.
Why it’s in the corpus
A one-stop, up-to-date comparative survey of every national PSSD label action — useful as a secondary source and as a cross-check list for the corpus's regulatory entries, plus documentation of the unresolved FDA petition and the 2024–2025 litigation.
Related records
- Peer-reviewed paper
Citizen petition: Sexual side effects of SSRIs and SNRIs
David Healy · International Journal of Risk & Safety in Medicine
This is the published text of a citizen petition asking the US FDA to require boxed warnings and label changes for all SSRI and SNRI products regarding persistent sexual dysfunction after discontinuation. The petition marshals the history of regulatory…
LIT-0202018PSSDLiterature sweep · Oct 2026 - Video
C-SPAN recorded the opening panel of the MAHA Institute's Mental Health and Overmedicalization Summit in Washington, DC (May 2026), where four young adults described harms they attribute to psychiatric drugs taken from childhood or adolescence. Cooper Davis…
CUR-0012026-05PSSDCurator additions - Regulatory document
Summary Safety Review — Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-norepinephrine Reuptake Inhibitors (SNRIs): Assessing the Potential Risk of Sexual Dysfunction despite Treatment Discontinuation
Health Canada · Health Canada Drug Product Vigilance (dhpp.hpfb-dgpsa.ca), resource SSR00254
Health Canada's published review of whether SSRI/SNRI sexual dysfunction can persist, worsen, or newly appear after stopping treatment. Its case review found 58 sexual-dysfunction reports, of which 43 (16 Canadian, 27 international) were judged possibly…
LIT-0712021-01PSSDLiterature sweep · Oct 2026